NCT01413308

Brief Summary

Developed in the early 1970s, Fontan Operation has provided palliative care for patients with single ventricle physiology. Single ventricle is a rare subclass of the atrioventricular (AV) alignment abnormalities double inlet and common inlet ventricles (and rarely, straddling tricuspid valve), in which there is only one ventricular sinus \[1\]. Most patients present with symptoms of congestion , low cardiac output, and deep cyanosis immedietly after birth. Untreated, these heart anomalies are highly lethal. Neonatal heart transplantation is implacable because of shortage of donors. Fontan operation is a three staged palliative procedure: the single ventricle pumping blood to the systemic circulation , while blood flows laminarly to the lungs through direct anastomosis of the superior and inferior vena cavae (total cavo pulmonary connections), inevitably by-passing the right heart . This procedure has been shown to immediately correct the mixed venous blood dysfunction, providing treatment for the prominent signs of cyanosis. Along with its beneficial outcomes, Fontan circulation patients have been documented to have a variety of post-operative late complications. Of most substantial, increased systemic vascular resistance (mean of 10-15 mmHg higher) \[2\], systolic dysfunction as a result of decreased preload and increase afterload \[3\], and atrial arrhythmias \[4\]. With the advent of bypassing right-heart circulation with Fontan operation, the pulmonary vascular bed is exposed to a new atmosphere of blood flow. Instead of physiological pulsatile flow in normal circulation, the pulmonary vasculature is receiving slow velocity, laminar flow \[5\]. Patients post-Fontan operations have been documented to have restrictive-type pulmonary function, but still yet to be correlated with Fontan circulation or as a possible result of prior lung tissue injury from the pre/intra-operation high volume blood flow. Regardless, Fontan patients are described to have decreased pulmonary function. The purpose of this research effort is to document and analyze the pulmonary function of those patients post-Fontan operation. It is still unclear as to what the long-term effects of Fontan operation are towards the pulmonary vascular bed, leaving us questions about the effects on lung capacities, ventilation-perfusion efficiency, and oxygen saturation.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2011

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 9, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 10, 2011

Completed
22 days until next milestone

Study Start

First participant enrolled

September 1, 2011

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
Last Updated

August 10, 2011

Status Verified

August 1, 2011

Enrollment Period

6 months

First QC Date

August 9, 2011

Last Update Submit

August 9, 2011

Conditions

Keywords

Fontanlung function testnitric oxide productionNYHA class 1-2 without acute or chronic specified lung disease

Eligibility Criteria

Age10 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

A total number of 15 Fontan patients , aged 10 years and older , with 1-2 NYHA class functional capacity. All will have total pulmonary function tests according to recognized pulmonary protocols. Results will be normalized to age-dependent pulmonogram. Exclusion criteria includes patients with acute pulmonary illness. Generation of Data: 1. Spirometry-Spirometry will be performed in accordance with ATS/ERS (American Thoracic Society/ European Respiratory Society) Task Force 2. Whole Body Plethysmography- FRCpleth will be measured 3. MCT - Methacholine challenge tests will be performed 4. FENO: Measurement of FENO will be performed by portable electrochemical analyzer NIOX MINO (Aerocrine AB, Smidesvägen, Sweden),\[10\] and according to ATS recommendations .

You may qualify if:

  • Fontan patient NYHA 1-2
  • Age - 10-99

You may not qualify if:

  • Pregnant woman
  • Acute pulmonary disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Asaad khoury, MD

    Rambam Health Care Campus

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 9, 2011

First Posted

August 10, 2011

Study Start

September 1, 2011

Primary Completion

March 1, 2012

Study Completion

September 1, 2012

Last Updated

August 10, 2011

Record last verified: 2011-08